Observational study on patients with ventricular tachycardia and cardiomyopathy
Prospective Cohort for the sEcoNDary Prevention of Ventricular Tachycardia in Patients With Cardiomyopathies (END-VT) Study
This study is tracking patients with heart muscle disease who experience fast heartbeats to see how well different treatments work and to help them live longer without heart problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2454 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nova Scotia Health Authority Academic / other |
| Locations | 3 sites (Vancouver, British Columbia and 2 other locations) |
| Trial ID | NCT05835791 on ClinicalTrials.gov |
What this trial studies
The END-VT study is a multicenter, prospective, longitudinal cohort study focusing on patients with cardiomyopathy-related ventricular tachycardia (VT). It aims to follow these patients from their first VT event for at least three years to determine the best treatment strategies for maximizing event-free survival. The study will also evaluate the epidemiology of VT, adherence to treatment guidelines, and the safety and effectiveness of current treatment options. Data will be collected through ICD remote monitoring and analyzed by clinical investigators to ensure unbiased results.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old with a documented diagnosis of sustained ventricular tachycardia and cardiomyopathy who are undergoing or planning to undergo ICD implantation.
Not a fit: Patients whose ventricular tachycardia is due to a reversible cause may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies that enhance survival rates and quality of life for patients with ventricular tachycardia and cardiomyopathy.
How similar studies have performed: Other studies have shown success in similar approaches to managing ventricular tachycardia, but this study aims to provide new insights specific to cardiomyopathy patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Documented sustained ventricular arrhythmia (\>30 seconds as documented by an ECG, cardiac monitor, AED, and/or intracardiac pacemaker/ICD electrograms (EGMs); 2. First (new) diagnosis of VT; 3. Presence of or plan for ICD implant during index hospitalization; 4. Diagnosis of cardiomyopathy (ie. ICM, hypertrophic, dilated, restrictive, arrhythmogenic cardiomyopathy, or other scar), 5. ICD clinic follow-up planned, and 6. Age \>18 years old Exclusion Criteria: 1\) Patients with VT due to a reversible cause
Where this trial is running
Vancouver, British Columbia and 2 other locations
- Providence Health Care Society — Vancouver, British Columbia, Canada (Recruiting)
- QEII Health Science Centre — Halifax, Nova Scotia, Canada (Recruiting)
- Montreal Heart Institute, — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Michelle Samuel, MPH, PhD — Montreal Heart Institute
- Study coordinator: John L Sapp, MD, FRCPC
- Email: john.sapp@nshealth.ca
- Phone: 902-473-4272
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.